{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-050789","form_type":"8-K","ticker":"CSBR","cik":"0000771856","company_name":"CHAMPIONS ONCOLOGY, INC.","filed_at":"2024-12-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.002607+00:00","generated_at":"2026-05-29T04:55:42.605565+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Champions Oncology Q2 FY2025: Revenue $13.5M, Net Income $730K, Adj. EBITDA $1.1M","bullets":["Q2 revenue rose 17% YoY to $13.5M; gross margin improved to 45% from 43%","Net income of ~$730K vs. $2.0M operating loss a year ago","Adjusted EBITDA of $1.1M, reversed from a $1.4M loss in Q2 FY2024","Company guides FY2025 revenue growth of at least 10%-15%, citing core strength and new data platform revenue","No debt; cash on hand ~$2.8M; data monetization highlighted as a transformative additional revenue stream"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-050789","json":"https://secwatch.observer/filing/0001628280-24-050789.json","markdown":"https://secwatch.observer/filing/0001628280-24-050789.md","text":"https://secwatch.observer/filing/0001628280-24-050789.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/771856/000162828024050789/0001628280-24-050789-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/771856/000162828024050789/csbr-20241211.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T04:55:42.605565+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}